Bausch Health acquires anti-itch drop under study
Bausch Health Companies and Eton Pharmaceuticals announced that a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals investigational eye drop.
Once FDA-approved, the agent would be an over-the-counter preservative-free formulation for the treatment of ocular itching associated with allergic conjunctivitis, Bausch said in a press release.
EM-100 has been submitted to the FDA for review, according to the company press release.
Previously, Eton Pharmaceuticals reported positive results from a phase 3 trial where the eye drop showed statistically significant superiority to placebo and no adverse events and demonstrated noninferiority to a comparator product for ocular itching.